Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Intellia Therapeutics

Clinical trials sponsored by Intellia Therapeutics, explained in plain language.

Intellia Therapeutics NTLA NASDAQ

A gene-editing company using CRISPR technology to develop therapies for genetic diseases.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 2 Not yet finished but already full! 4 Completed 1

Gene editing breakthrough? CRISPR therapy targets rare amyloidosis

Disease control Completed

This early-stage trial tests NTLA-2001, a CRISPR-based gene editing therapy, in 72 adults with hereditary ATTR amyloidosis—a condition where abnormal protein builds up in nerves or the heart. The treatment aims to turn off the faulty gene to reduce protein levels. The study focus…

Phase: PHASE1 • Sponsor: Intellia Therapeutics • Aim: Disease control

Last updated Jun 27, 2026 09:00 UTC